UNSPSC 51291501: Feprosidnine

This classification denotes an antidepressant agent with the molecular formula C11H13N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1G4W8NR1PT, chemically known as 3-(1-methyl-2-phenylethyl)sydnone imine, monohydrochloride but generally known as feprosidnine, which bears US NIH Compound Identifier 72088. European Medicines Agency schedules Feprosidnine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07609MIG.

UNSPSC 51291501 Feprosidnine, a Commodity code, covers pharmaceutical products that state and local governments procure to support public health and community health initiatives. Recent solicitations show state and local buyers acquiring naloxone (opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The code reflects procurement activity across health departments and community health facilities seeking to stock emergency medications, harm-reduction supplies, and standard pharmacy inventories for public health programs and employee health plans.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to its Community Health Building in Sanford, Florida, with a July 26, 2023 response deadline. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for direct-to-manufacturer prescription programs to support its pharmacy benefit program, signaling forward movement toward formal procurement of pharmaceutical supply chain services. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 deadline, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring products available by May 1, 2026, with an effective contract date of July 1, 2026.